Long-acting VEGF inhibitors for intraocular neovascularization
View Patent ↗Compositions and methods for treating a VEGF-related ophthalmic disorder in a subject in need comprising, administering intravitreally to the subject a therapeutically effective amount of an anti-VEGF agent, comprising a VEGF binding portion operatively linked to a Fc-IgG, wherein the VEGF binding portion comprises at least one VEGF binding domain that is an IgG-like domain 2 of VEGFR-1.
1. A method of treating a VEGF related condition in an eye of a subject comprising: administering to the eye an anti-VEGF agent consisting of the amino acid residues 27 to 459 of SEQ ID NO: 3.
2. The method of claim 1 , wherein the administering comprises an intravitreal injection.
3. The method of claim 1 , wherein the VEGF related condition comprises neovascularization.
4. The method of claim 3 , wherein the neovascularization is choroidal neovascularization.
5. The method of claim 3 , wherein the neovascularization is retinal neovascularization.
6. The method of claim 3 , wherein the VEGF related condition is age-related macular degeneration.